- Home
- NIVF vs BCDA Comparison
NIVF vs BCDA Comparison
Compare NIVF & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- BCDA
- Stock Information
- Founded
- NIVF 2011
- BCDA N/A
- Country
- NIVF Thailand
- BCDA United States
- Employees
- NIVF N/A
- BCDA N/A
- Industry
- NIVF
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- BCDA Health Care
- Exchange
- NIVF NYSE
- BCDA Nasdaq
- Market Cap
- NIVF 12.2M
- BCDA 7.9M
- IPO Year
- NIVF N/A
- BCDA N/A
- Fundamental
- Price
- NIVF $1.16
- BCDA $2.60
- Analyst Decision
- NIVF
- BCDA Strong Buy
- Analyst Count
- NIVF 0
- BCDA 1
- Target Price
- NIVF N/A
- BCDA $25.00
- AVG Volume (30 Days)
- NIVF 11.9M
- BCDA 74.1K
- Earning Date
- NIVF 11-16-2024
- BCDA 11-06-2024
- Dividend Yield
- NIVF N/A
- BCDA N/A
- EPS Growth
- NIVF N/A
- BCDA N/A
- EPS
- NIVF 0.21
- BCDA N/A
- Revenue
- NIVF $5,136,153.00
- BCDA $428,000.00
- Revenue This Year
- NIVF N/A
- BCDA $6.92
- Revenue Next Year
- NIVF N/A
- BCDA N/A
- P/E Ratio
- NIVF $5.39
- BCDA N/A
- Revenue Growth
- NIVF N/A
- BCDA 0.71
- 52 Week Low
- NIVF $0.55
- BCDA $1.96
- 52 Week High
- NIVF $17.24
- BCDA $23.25
- Technical
- Relative Strength Index (RSI)
- NIVF 56.42
- BCDA 46.60
- Support Level
- NIVF $1.07
- BCDA $2.39
- Resistance Level
- NIVF $3.28
- BCDA $2.84
- Average True Range (ATR)
- NIVF 0.42
- BCDA 0.17
- MACD
- NIVF 0.05
- BCDA -0.00
- Stochastic Oscillator
- NIVF 22.42
- BCDA 41.18
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).